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Expression of microRNAs 16, 20a, 
150 and 155 in anal squamous 
intraepithelial lesions from high-
risk groups
Andreia Albuquerque  1,2, Mara Fernandes  3, Oliver Stirrup4, Ana Luísa teixeira3, 
Joana Santos  3, Marta Rodrigues5, Elisabete Rios1,5,6, Guilherme Macedo1,2 & 
Rui Medeiros1,3,7,8
Anal squamous intraepithelial lesions (ASIL) or anal intraepithelial neoplasia (AIN) are precancerous 
lesions. microRNAs (miRNAs) have been implicated in cervical carcinogenesis, but have never been 
assessed in anal precancerous lesions. Our aim was to evaluate the expression of miR-16, miR-20a, 
miR-150 and miR-155 in several grades of ASIL obtained from high-risk patients, submitted to anal 
cancer screening from July 2016 to January 2017. Lesions were classified according to the Lower 
Anogenital Squamous Terminology (LAST) in low-grade (LSIL) and high-grade squamous intraepithelial 
lesions (HSIL), and the AIN classification in AIN1, AIN2 and AIN3. A hundred and five biopsies were 
obtained from 60 patients. Ten samples were negative (9.5%), 63 were LSIL (60%) and 32 were HSIL 
(30.5%) according to the LAST. Twenty seven (26%) were negative for dysplasia, 46 were classified as 
AIN1 (44%), 14 as AIN2 (13%) and 18 as AIN3 (17%) according to the AIN classification. There was no 
statistically significant difference in the fold expression of miR-16, miR-20a, miR-150 and miR-155, 
according to either classification. Although non- significant, there was an increasing trend in the miR-
155 fold expression from negative samples to HSIL, with the highest fold expression increase in both 
LSIL and HSIL compared to the other miRNAs.
Anal squamous cell carcinoma (SCC) is strongly associated with anal human papillomavirus (HPV) infection, 
which has been observed to be present in nearly 90% of the cases1. The prevalence has been increasing in recent 
years in many populations, especially in Northern and Western Europe, America and Australia2, and it is expected 
to continue to grow in the coming decades3,4.
The terms anal squamous intraepithelial lesions (ASIL) or anal intraepithelial neoplasia (AIN) are used to 
describe anal SCC premalignant lesions. The Lower Anogenital Squamous Terminology (LAST) published in 
2012, recommended that anogenital squamous intraepithelial lesions be classified as either low-grade squamous 
intraepithelial lesions (LSIL) or high-grade squamous intraepithelial lesions (HSIL) in all anogenital sites5. This 
classification replaced the former 3-tiered system that in the anal canal included the terms AIN1 (mild dyspla-
sia) as low-grade lesions, AIN2 (moderate dysplasia) and AIN3 (severe dysplasia) as high-grade lesions. This 
differentiation between low and high-grade lesions is relevant for treatment indication, prognosis and follow-up. 
High-grade squamous intraepithelial lesions have a higher progression rate for cancer and treatment is nor-
mally advocated. Biomarkers can have an important role in the classification of anogenital squamous intraep-
ithelial lesions5, by reducing inter- and intraobserver variability6,7. Currently, only p16 immunohistochemistry 
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is recommended in specific cases, such as -IN2 cases (−IN2/p16 negative considered low-grade and −IN2/p16 
positive as high-grade lesions)5. p16 is the best performing biomarker for classification currently available, but 
is not ideal5, with the possibility of false positives (7% of all anal LSIL will be p16 positive) and subsequent over-
treatment, or false negative results and subsequent undertreatment (24% of AIN2 and 10% of AIN3 will be p16 
negative)8.
microRNAs (miRNAs) are noncoding RNAs, approximately 21–23 nucleotides in length that have been stud-
ied and implicated in several types of cancers, acting as tumour suppressors or oncogenes (oncomirs)9. Research 
involving miRNAs may provide insight into HPV-related carcinogenesis and possible new biomarkers for cancer 
diagnosis, and determination of prognosis and optimal therapy9. Several studies have implicated multiple miR-
NAs in key pathways linked to cervical cancer, such as cell proliferation, apoptosis, migration and invasion10. 
Many of these studies compared miRNA expression in cervical SCC with that in normal cervical mucosa10. There 
are also studies that have evaluated the expression in cervical precancerous lesions, mostly with relatively small 
sample sizes10.
Anal and cervical carcinogenesis are considered to be very similar HPV-driven processes, although important 
differences exist. The incidence rate is much higher for cervical cancer, and there is a lower progression rate from 
anal high-grade lesions to cancer11. There are specific high-risk groups for HPV-related anal lesions, namely 
HIV-positive patients, especially those who are men who have sex with men (MSM)11,12, solid organ transplant 
recipients13–15 and women with a previous history of genital neoplasia16–19. Information on several aspects of anal 
carcinogenesis is still scarce, and much of our understanding and the approaches used for investigation have 
drawn on our knowledge of the cervix.
As far as we know, miRNAs have not previously been assessed in ASIL. The aim of this study was to evaluate 
the expression of miR-16, miR-20a, miR-150 and miR-155 in several histological grades of ASIL, obtained from 
high-risk patients. This miRNA panel was chosen based on published data related to cervical carcinogenesis, HPV 
infection and cell cycle influence10.
Results
In total, 105 biopsies were obtained from 60 patients with a mean age of 42 ± 13 years. Fifty-three patients were 
HIV-positive (88%), 51 patients were men (85%), all men were men who have sex with men, and six of the 
nine women included had a previous history of genital neoplasia (67%). Two patients were on immunosuppres-
sive drugs (3%), both were women also with a previous history of genital neoplasia. HPV 16 anal infection was 
detected in 28 patients (47%), HPV 18 in 18 patients (30%) and HR-HPV other than HPV 16/18 (but not exclud-
ing patients with HPV 16/18 coinfection) in 49 patients (82%), Table 1.
Ten samples were negative (9.5%), 63 were classified as LSIL (60%) and 32 as HSIL (30.5%) according to the 
LAST, with 95 ASIL in total. When considering the AIN classification, 27 (26%) were negative for dysplasia, 46 
were classified as AIN1 (44%), 14 as AIN2 (13%) and 18 as AIN3 (17%), with a total of 78 AIN samples. Of the 
biopsies, 85 were anal (81%) and 20 were perianal (19%), Table 1.
Of the 60 patients included, there were 26 patients (43%) in whom biopsies were performed for more than one 
anal/perianal area, targeting different lesions. Information on the histological classification of the samples accord-
ing to the LAST and AIN classification per patient are presented in Supplementary Tables S1 and S2, respectively.
There was no statistically significant difference in the fold expression of miR-16, miR-20a, miR-150 and miR-
155 for anal/perianal LSIL and HSIL according to LAST, although an increasing trend in the fold expression was 
seen from negative to HSIL for miR-155. The highest fold expression increase in both LSIL and HSIL samples 
were seen for miR-155, (Table 2). Boxplots of ΔCt values for each miRNA according to LAST classification can 
be seen in the Fig. 1.
There was also no statistically significant difference in the fold expression of miR-16, miR-20a, miR-150 and 
miR-155 for AIN1, AIN2 and AIN3 according to AIN classification. AIN2 samples showed the highest level 
of expression for miR-20a, miR-150 and miR-155, the highest difference was observed for miR-150 (Table 2). 
Boxplots of ΔCt values for each miRNA according to AIN classification can be seen in the Fig. 2.
There was no statistically significant different change in expression of these miRNAs according to the histolog-
ical grade when analyses were adjusted for age, anal HPV genotype, lesion location, sex, HIV-positivity, smoking 
status or history of previous genital neoplasia (data not shown). There was no statistically significant difference 
in expression of these miRNAs according to HIV status or presence of high-risk HPV when these variables were 
used to adjust estimates for lesion classification or when analysed alone.
Discussion
There are several studies showing an up-regulation of miR-1620–23, miR-20a24–27, miR-15028,29 and miR-15521–23,30 
in cervical SCC (in comparison to normal mucosa). The expression of miRNA-20a24,25,31 and miRNA-15028,29 was 
also found to be associated with a worse cervical cancer prognosis. The miR-20a promotes migration and inva-
sion by regulating tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 (TNKS2) expression in 
human cervical SCC cells27. TNKS2 overexpression can increase telomere length, acting as an oncogene32,33. The 
miR-150 modulates FOXO4 expression, resulting in cervical cancer cell growth and survival28.
The miR-16 has previously been recognized as a tumor-suppressive miRNA10,34, with decreased expression 
in several different cancers, but not in cervical cancer10. In cervical intraepithelial lesions (CIN), Wang et al.20 
found an increasing trend of expression in CIN3, although non-statistically significant, when comparing normal 
(n = 38), CIN1/2 (n = 13) and CIN3 samples (n = 39). The miR-20a is part of the miR-17-92 cluster, and in one 
study it was shown that it was upregulated in the serum of CIN patients compared with those from the healthy 
controls35. In a study by Wilting et al.21, miR-150 expression was higher in CIN 2/3 samples (n = 18) vs. normal 
cervical samples (n = 10), although this result needs to be interpreted with caution due to the small sample size.
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The miR-155 is a recognized oncomiR, promoting cervical cancer cell proliferation through suppression of 
LKB1 (tumor suppressor in cervical cancer)30. Two studies21,36 evaluating the expression in CIN2/3 samples vs. 
normal samples, failed to show a statistically significant higher expression in CIN2/3 samples, although there was 
an increasing trend in CIN2/3. miR-155 results in cervical studies/CIN samples are similar to this study: when 
comparing anal normal (n = 10) and anal HSIL samples (n = 32), although there was no statistically significant 
difference, a higher fold expression was seen in HSIL.
Using the AIN classification, the highest fold expression of miR-20a, miR-150 and miR-155 was seen in AIN2 
samples, although this was non-statistically significant. In cervical studies involving these miRNAs, CIN2 sam-
ples were not analysed separately, so previous information regarding this is not available. We cannot rule out 
large average differences in expression between histological grades, but the observed distributions of values in 
individual samples clearly overlap greatly across histological grades indicating a lack of clear-cut differentiation.
The maximum number of CIN samples that have been previously tested for any of these four miRNAs in a 
single study was 52 samples (in this case for miR-16)20. As far as we know, the present study included the largest 
number of anogenital precancerous lesions tested for miRNA expression10, and histology was described according 
to both the AIN and the LAST classifications (in previous cervical studies only a single classification was used). 
The former AIN/CIN classification is still widely used, especially in Europe. An association between several (risk) 
factors and the fold expression of miRNAs was also conducted to understand how these factors could possibly 
influence the expression in histological grades.
Data from previous cervical studies provided important guidance for the choice of our miRNA panel, given 
the similarities between the two HPV-driven carcinogenic processes. In both cases, HPV is recognized as the 
major etiologic agent, there is a similar more susceptible histological area (squamocolumnar junction) and the 
same type of precancerous lesions (CIN/AIN). Most of the research in HPV-linked anogenital disease is focused 
on the cervix, with findings then commonly generalized to the anal canal. These generalizations are impaired by 
the fact that the cervix is by far the anatomical region most commonly affected by HPV-related lesions, and the 
Parameter Value
Patients Features
Men, n (%) 51 (85)
  MSM, n (%) 51/51 (100)
Female (%) 9 (15)
    Women with previous history of genital 
neoplasia, n (%) 6/9 (67)
Age (years), mean ± SD 42 ± 13
HIV-positive, n (%) 53 (88)
  CD4 (cells/mm3) sample collection, mean ± SD 628 ± 278
Previous history of anal squamous cell 
carcinoma, n (%) 1 (2)
Pharmacologically immunosuppression, n (%) 2 (3)
Current or past smoking history, n (%) 19/45 (42)
Unknown history of smoking (missing data) 15/60 (25)
Anal HPV 16 positivity, n (%) 28 (47)
Anal HPV 18 positivity, n (%) 18 (30)
Other anal high-risk HPV*, n (%) 49 (82)
HPV negative/low-risk, n (%) 7 (12)
Samples Features
LAST Classification
  Negative, n (%) 10 (9.5)
  LSIL, n (%) 63 (60)
  HSIL, n (%) 32 (30.5)
AIN Classification
  Negative for dysplasia, n (%) 27 (26)
  AIN1, n (%) 46 (44)
  AIN2, n (%) 14 (13)
  AIN3, n (%) 18 (17)
Samples Location
  Anal, n (%) 85 (81)
  Perianal, n (%) 20 (19)
Table 1. Overall data of the patients (n = 60) and samples included in this study (n = 105). AIN: anal 
intraepithelial neoplasia; HPV: human papillomavirus; HSIL: high-grade squamous intraepithelial lesions; 
LAST: lower anogenital tract terminology; LSIL: low-grade squamous intraepithelial lesions; MSM: men 
who have sex with men. *High-risk HPV other than HPV16/18 (but not excluding patients with HPV 16/18 
coinfection).
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progression rate of high-grade lesions in the cervix is around 1/80 per year vs. 1/377 per year in the anal canal 
(HIV-positive MSM in the highly active antiretroviral therapy era)11. Anal SCC is a largely HPV-driven disease 
(mainly HPV16), involving high-risk groups, with a very low prevalence in the general population, as for HSIL/
AIN3 (also associated with HPV 16)37. These known differences, and the expected increase in incidence of anal 
SCC3,4 justify specific studies involving the anus.
The expression of these miRNAs in CIN samples showed, in most cases, an increasing trend in more severe 
grades (although non-statistically significant)20,21,36. Further studies with a large number of precancerous samples, 
including several grades of lesions, are important to clarify any possible association.
A large majority of patients included were HIV-positive MSM because this is the population with highest 
risk for anal SCC, and in which anal cancer screening has been recommended38. There have been several stud-
ies evaluating the involvement of cellular miRNAs during HIV infection, and as a potential biomarker in these 
populations39–42. One study showed that HIV-infected individuals with low or undetectable viral load exhibit a 
gene expression profile very similar to control or uninfected subjects41. Another study, analysing miRNA-150 
(“anti-HIV miRNA”) levels in the peripheral blood of mononuclear cells of HIV-positive patients revealed that 
ΔCt (95% CI) ΔΔCt (95% CI) 2−ΔΔCt (95% CI) P-value*
LAST classification
microRNA20a
Negative 1.7 (−0.47 to 3.88) 0.814
LSIL 0.94 (0.03 to 1.85) −0.76 (−3.08 to 1.55) 1.7 (0.34 to 8.44) 0.518
HSIL 1.04 (−0.19 to 2.26) −0.67 (−3.12 to 1.78) 1.59 (0.29 to 8.68) 0.593
microRNA150
Negative 0.72 (−1.79 to 3.24) 0.874
LSIL 0.74 (−0.34 to 1.82) 0.02 (−2.64 to 2.68) 0.99 (0.16 to 6.24) 0.990
HSIL 0.3 (−1.12 to 1.72) −0.42 (−3.23 to 2.38) 1.34 (0.19 to 9.38) 0.768
microRNA155
Negative 3.53 (1.22 to 5.84) 0.321
LSIL 2.19 (1.23 to 3.15) −1.34 (−3.81 to 1.13) 2.53 (0.46 to 14.03) 0.287
HSIL 1.54 (0.23 to 2.84) −1.99 (−4.61 to 0.62) 3.98 (0.65 to 24.41) 0.135
microRNA16
Negative −0.92 (−3.54 to 1.7) 0.930
LSIL −1.02 (−2.1 to 0.07) −0.1 (−2.9 to 2.7) 1.07 (0.15 to 7.45) 0.945
HSIL −0.68 (−2.15 to 0.8) 0.24 (−2.72 to 3.2) 0.85 (0.11 to 6.61) 0.874
AIN classification
microRNA20a
No dysplasia 1.16 (−0.12 to 2.44) 0.309
AIN1 0.94 (−0.11 to 1.99) −0.22 (−1.78 to 1.34) 1.16 (0.39 to 3.44) 0.785
AIN2 −0.21 (−1.94 to 1.53) −1.37 (−3.44 to 0.71) 2.58 (0.61 to 10.87) 0.196
AIN3 1.96 (0.39 to 3.53) 0.8 (−1.14 to 2.74) 0.57 (0.15 to 2.21) 0.419
microRNA150
No dysplasia 0.97 (−0.51 to 2.45) 0.461
AIN1 0.57 (−0.66 to 1.8) −0.39 (−2.17 to 1.38) 1.31 (0.38 to 4.5) 0.664
AIN2 −0.77 (−2.75 to 1.2) −1.74 (−4.08 to 0.6) 3.34 (0.66 to 16.88) 0.145
AIN3 1.11 (−0.69 to 2.92) 0.15 (−2.05 to 2.35) 0.9 (0.2 to 4.15) 0.895
microRNA155
No dysplasia 2.64 (1.26 to 4.03) 0.612
AIN1 2.19 (1.06 to 3.31) −0.46 (−2.16 to 1.25) 1.37 (0.42 to 4.48) 0.601
AIN2 1.07 (−0.82 to 2.97) −1.57 (−3.85 to 0.71) 2.97 (0.61 to 14.39) 0.177
AIN3 1.86 (0.15 to 3.56) −0.79 (−2.91 to 1.34) 1.73 (0.4 to 7.53) 0.468
microRNA16
No dysplasia −0.37 (−1.92 to 1.18) 0.606
AIN1 −1.42 (−2.68 to −0.17) −1.05 (−2.97 to 0.87) 2.07 (0.55 to 7.85) 0.282
AIN2 −1.29 (−3.42 to 0.84) −0.92 (−3.49 to 1.65) 1.89 (0.32 to 11.22) 0.483
AIN3 −0.21 (−2.12 to 1.7) 0.16 (−2.23 to 2.55) 0.9 (0.17 to 4.69) 0.896
Table 2. Mean ΔCt and ΔΔCt values according to LAST and AIN classifications estimated using linear mixed 
effects models. ΔΔCt and P-values are displayed for comparison relative to reference group. *P-value in top 
row for each microRNA is likelihood ratio test for differences across all histological grades for each comparison, 
other P-values are calculated by Wald test for each grade in fitted model. AIN: anal intraepithelial neoplasia; 
CI: confidence interval; HSIL: high-grade squamous intraepithelial lesions; LAST: lower anogenital tract 
terminology; LSIL: low-grade squamous intraepithelial lesions.
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they are restored after highly active antiretroviral therapy, with no difference also shown for miRNA-16 levels 
according to HIV status/therapy42. There is no indication for providing anal cancer screening in healthy popu-
lations, so we do not have data/anal samples in low-risk controls/healthy individuals. Our HIV-positive cohort 
was homogeneous, with all patients well controlled on highly active antiretroviral therapy, so an effect of HIV 
status on the anal expression of miRNAs seems unlikely (with a different expression in high-risk patients relative 
to normal low-risk controls).
There are some limitations to be considered, although the number of anal samples included, for some compar-
isons of histological grades such as AIN2, the samples size is small. For estimates of miRNA expression in abnor-
mal tissue relative to normal samples the confidence intervals for estimates were wide, meaning that large average 
differences between groups cannot be completely ruled out. There was a small number of samples for which p16 
immunostaining was performed (n = 19), so comparison of miRNA expression according to p16 results have not 
been presented. There were only two patients on pharmacological immunosuppression (both were women with a 
previous history of genital neoplasia) and one patient with a previous history of anal SCC, so the impact of these 
features in miRNA expression was not analysed. These three patients, although in a small number, fit our inclu-
sion criteria of high-risk patients for anal SCC who underwent anal cancer screening, and so were included. There 
was no association between miRNA expression and HPV presence or HIV status, but the numbers of patients 
who were HPV and HIV-negative are small.
This is the first ever study evaluating the expression of miRNAs in ASIL. Our findings indicate that at present, 
miR-16, miR-20a, miR-150 and miR-155 expression cannot be considered as biomarkers for the histological clas-
sification/differentiation of these lesions. There is also no indication, that our data in the anus and the previous 
published data in cervix, might be largely different at this level. For miR-155, although not statistically significant, 
there was an increasing trend in fold expression from negative samples to HSIL. The highest fold expression 
increase in both anal LSIL and HSIL was seen for this miRNA, and future studies might explore this further.
Methods
Study design and study population. This was a cross-sectional study, with recruitment of a sample of 
high-risk patients followed for anal SCC screening, from July 2016 to January 2017, in the Proctology outpatient 
clinic of Gastroenterology Department of Centro Hospitalar S. João, Porto, Portugal. Both first screening visits 
and follow-up visits were considered. Inability to provide written consent was an exclusion criteria. Any possible 
case with a suspicious lesion for anal SCC was not considered for this study. Information regarding gender, age at 
sample collection, smoking history, HIV-positivity, sexual orientation in men, previous history of genital neopla-
sia, pharmacological immunosuppression and previous anal SCC history were recorded.
Figure 1. Boxplots of ΔCt values for each microRNA according to LAST classification of sample. HSIL: high-
grade squamous intraepithelial lesions; LAST: lower anogenital tract terminology; LSIL: low-grade squamous 
intraepithelial lesions. Lower and upper limits of boxes represent lower and upper quartiles, respectively, 
the internal line is the median and the ‘whiskers’ show the range. Observations below ‘lower quartile −1.5* 
interquartile range (IQR)’ or above ‘upper quartile +1.5* IQR’ are not included in the range but are plotted 
individually (●).
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Informed verbal and written consent was obtained from all patients that accepted entering the study. This 
study was approved by the Health Ethics Committee of Centro Hospitalar S. João and was performed in accord-
ance with the 1964 Declaration of Helsinki and its later amendments.
High-resolution anoscopy and sample collection. All patients underwent high-resolution anoscopy 
and anal/perianal biopsies were collected during the routine patient assessment, under high-resolution anoscopy. 
This technique was performed using a Carl Zeiss® colposcope (Carl Zeiss, Oberkochen, Germany), with patients 
observed in the knee–chest position (all procedures were performed by A.A.) An anoscope was inserted, and anal 
and perianal assessment was carried out under magnification, with a colposcope. Initially this was done without 
staining, and then 5% acetic acid and Lugol’s solution were used. Biopsies were performed using a mini-Tischler 
punch-biopsy forceps. No local anaesthesia was necessary for anal biopsies, for perianal biopsies a 1% lidocaine 
buffered with 8.4% of sodium bicarbonate was used. Two fragments were obtained, one for histological assess-
ment and one fragment was frozen at −80 °C for miRNA analysis. The number of biopsies performed in each 
patient was determined by the number of lesions seen. When biopsies were done in several anal/perianal areas in 
the same patient, they were always targeting different lesion locations and normally done in the same procedure.
An anal cytology sample, collected as part of the regular follow-up/screening of these patients, was used 
for HPV genotyping (the cytology results themselves were not included for this analysis). Anal cytology was 
performed using a sterile polyester swab (Thermo Fisher Scientific, Waltham, Massachusetts, USA), previously 
moistened with water, with the patients in the knee–chest position. The swab was inserted in the distal rectum 
and then slowly withdrawn with rotational movements over a period of 20 seconds. Samples were placed into 
PreservCyt ThinPrep® solution (Hologic UK, Crawley, UK).
Histological analysis. Histological samples were analysed in the Pathology Department of Centro 
Hospitalar S. João in Porto, Portugal, by experienced Pathologists using the same protocol and with consensus 
discussion of all difficult or equivocal cases. For this study, two histological classifications were recorded. One was 
according to the AIN classification (three-tiered nomenclature), using the presence/absence and grade of dys-
plasia: AIN1 (mild dysplasia), AIN2 (moderate dysplasia) and AIN3 (severe dysplasia). The other classification 
was according to the LAST5 two-tiered nomenclature: LSIL and HSIL. p16 immunohistochemistry was evaluated 
in equivocal cases as recommended by LAST guidelines, and p16-positive lesions were considered HSIL and 
p16-negative as LSIL5.
Negative biopsies obtained from the same group of high-risk patients were included in the analyses for com-
parison. The definition for negative anal biopsies is different in the two classifications and results were analysed 
accordingly. Anal biopsies with normal mucosa/reactive changes and non-dysplastic ASIL (including condylo-
mas) were considered “negative for dysplasia”, according to the AIN classification. According to the LAST5 only 
anal biopsies with normal mucosa/reactive changes were considered “negative” since the sheer presence of a 
Figure 2. Boxplots of ΔCt values for each microRNA according to AIN classification of sample. AIN: anal 
intraepithelial neoplasia. Lower and upper limits of boxes represent lower and upper quartiles, respectively, 
the internal line is the median and the ‘whiskers’ show the range. Observations below ‘lower quartile −1.5* 
interquartile range (IQR)’ or above ‘upper quartile +1.5* IQR’ are not included in the range but are plotted 
individually (●).
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cytopathic effect of HPV (koilocytosis) and condyloma, even without dysplasia, are considered LSIL (koilocytosis 
and condyloma are usually a non-dysplastic ASIL).
HPV genotyping. For this analysis, the remaining sample of the liquid-based anal cytology specimen that 
was collected during the normal patient assessment was used. HPV genotyping was performed using the cobas® 
HPV test. The test simultaneously provides pooled results for 12 high-risk (HR) genotypes (HPV 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66, and 68) and individual results for HPV 16 and HPV 18. A negative result indicates either 
the absence of any HPV or the presence of only low-risk HPV infection (HPV 6 and 11). This analysis was con-
ducted in the Pathology Department of Centro Hospitalar S. João in Porto, Portugal.
The procedure was performed following the manufacturer’s instructions. Initially, the DNA extraction (HPV 
nucleic acids and the control β-globin DNA) was carried out using the fully automated cobas x 480 instrument. 
The cobas z 480 analyzer was then used for real-time polymerase chain reaction (PCR) amplification of HR-HPV 
and a β-globin DNA. The interpretation of the results was accomplished using the software provided with the 
cobas z 480 analyzer.
microRNA analysis. This analysis was conducted in the Portuguese Oncology Institute of Porto Research 
Center (CI-IPOP). The expression of four target miRNAs, miR-16, miR-20a, miR-150 and miR-155 and endoge-
nous controls (RNU-44 and RNU-48) were assessed using TaqMan® technology. An investigator blinded to the 
histological grade of the lesions carried out the miRNA assays (M.F.).
Briefly, the tissue samples were homogenized and macerated into TripleXtractor reagent (Grisp- research solu-
tions®) and using a syringe and 21 g needle. For miRNA isolation, the total RNA fraction was first isolated with a 
chloroform solution (Merck®) according Santos et al.42 protocol and for the purification we used the commercial 
kit GRS microRNA Kit (Grisp- research solutions®) after adjustments43,44.
The miRNA samples were then used as templates for cDNA synthesis using a Taqman®MicroRNA Reverse 
Transcription kit (Applied Biosystems®) and sequence specific stem-loop primers for hsa-miR-16, hsa-miR-20a, 
hsa-miR-150, hsa-miR-155, RNU-44 and RNU-48.
Based on a literature search encompassing studies on miRNA normalization in the cervical tissue, we selected 
RNU44 and RNU48 as endogenous candidate reference genes22,45,46. RNU-48 was used as an endogenous control 
for data normalization since it presented a stable expression pattern, meaning low mean delta threshold cycle 
values and standard deviation variations.
The thermal conditions were 16 °C for 30 minutes, followed by 42 °C for 60 minutes and 85 °C for 10 minutes 
as mention in Dias et al.43. The expression levels were analyzed by relative quantitative real-time PCR using a 
StepOne™qPCR Real-Time PCR machine. The reaction containing 1 × TaqMan® Fast Advanced Master Mix 
(Thermo Fisher Scientific®), 1 × probes (TaqMan® microRNA Expression Assays, miR-16: 000391; miR-150: 
000473; miR-155: 002623; miR-20a: 000580; RNU-44: 001094; and RNU-48: 001006, Thermo Fisher Scientific®) 
and cDNA sample (~50 ng). Two technical replicates were made for each sample.
The amplification conditions were holding stage 95 °C for 20 seconds, followed by 45 cycles of 95 °C for 
1 second and 60 °C for 20 seconds. Data analysis was performed using StepOne™Sofware v2.2 (Thermo Fisher 
Scientific®) with the same baseline and threshold set for each plate, in order to generate quantification cycle val-
ues for all the miRNAs in each sample.
Outcomes. The primary outcome was to evaluate the expression of miR-16, miR-20a, miR-150 and miR-155 
according to histological grade of the ASIL, using both the LAST and AIN classification. The secondary out-
come was to evaluate factors that can modify the fold expression of these miRNAs, according to the histological 
grading.
Statistical analysis. Continuous variables were described as mean ± standard deviation and categorical var-
iables were described as absolute and relative frequencies.
microRNAs expression was initially quantified as delta threshold cycle values (ΔCt), defined as Ct target 
miRNA minus Ct RNU48. The mean Ct value of a given miRNA from normal/negative anal biopsies served as a 
basal level to calculate the relative level of the miRNA detected in each type of lesion.
There were several lesions seen in some patients (one biopsy for each lesion was taken), so analyses were 
conducted using random intercept models with outcome variables on the ΔCt scale. For the primary analyses 
‘negative’ biopsies were treated as the reference categories and the average difference in ΔCt was estimated for 
each level of the LAST and AIN classifications, respectively. The model for each classification therefore provided 
estimates of ΔΔCt for each category of lesion relative to the reference group. The estimated ΔΔCt values and 
their 95% confidence interval (CI) were transformed to obtain estimates of relative change in expression normal-
ized to an endogenous reference (RNU48) (2−ΔΔCt)47 for interpretation. The 2−ΔΔCt value for ‘negative’ biopsies 
was 1 by definition.
Analyses were conducted to evaluate expression of the miRNAs according to histological grade (both clas-
sifications) with adjustment for each of the following patient characteristics: age (linear effect), anal HR-HPV 
positivity (any of the 12 possible types detected), HPV 16 positivity, HPV 18 positivity, lesion location (anal or 
perianal), sex, HIV-positivity, smoking status and a history of previous genital neoplasia. These analyses were 
again conducted using univariable linear mixed models with a random intercept term for each patient, and 
included all samples.
Statistical analysis was performed using Stata, version 14.1 (StataCorp, College Station, TX, USA).
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